Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Hawkins

Showing results (561-570 of 570) with videos related to

Pageof 57
Sort By:
You have reached the last page of results.This site can display upto 570 results.
Klinische Padiatrie|May 19, 2015
Development of curative therapies for Ewing sarcomas by interdisciplinary cooperative groups in EuropeT Bölling, G Braun-Munzinger, S Burdach, et al.
The New England Journal of Medicine|February 22, 2018
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and ChildrenAlexander Drilon, Theodore W Laetsch, Shivaani Kummar, et al.
Science Signaling|November 22, 2018
The HDAC3-SMARCA4-miR-27a axis promotes expression of the <i>PAX3:FOXO1</i> fusion oncogene in rhabdomyosarcomaNarendra Bharathy, Noah E Berlow, Eric Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2022
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Nathalie Gaspar, Katherine Janeway, et al.
Journal of the National Cancer Institute|September 25, 2025
SMARCAL1 is a new osteosarcoma predisposition geneMaryam Rafati, Lillian M Guenther, Laura E Egolf, et al.
Cancer Cell|December 17, 2013
Targeting oxidative stress in embryonal rhabdomyosarcomaXiang Chen, Elizabeth Stewart, Anang A Shelat, et al.
Neurology|April 13, 2005
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severityR H S R Roxburgh, S R Seaman, T Masterman, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2021
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Claudia Rossig, Crystal Mackall, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohortSigbjørn Smeland, Stefan S Bielack, Jeremy Whelan, et al.
The Lancet. Oncology|August 30, 2016
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trialNeyssa M Marina, Sigbjørn Smeland, Stefan S Bielack, et al.
Pageof 57

Showing results (561-570 of 570) with videos related to

Sort By:
Pageof 57
You have reached the last page of results.This site can display upto 570 results.
Klinische Padiatrie|May 19, 2015
Development of curative therapies for Ewing sarcomas by interdisciplinary cooperative groups in EuropeT Bölling, G Braun-Munzinger, S Burdach, et al.
The New England Journal of Medicine|February 22, 2018
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and ChildrenAlexander Drilon, Theodore W Laetsch, Shivaani Kummar, et al.
Science Signaling|November 22, 2018
The HDAC3-SMARCA4-miR-27a axis promotes expression of the <i>PAX3:FOXO1</i> fusion oncogene in rhabdomyosarcomaNarendra Bharathy, Noah E Berlow, Eric Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2022
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Nathalie Gaspar, Katherine Janeway, et al.
Journal of the National Cancer Institute|September 25, 2025
SMARCAL1 is a new osteosarcoma predisposition geneMaryam Rafati, Lillian M Guenther, Laura E Egolf, et al.
Cancer Cell|December 17, 2013
Targeting oxidative stress in embryonal rhabdomyosarcomaXiang Chen, Elizabeth Stewart, Anang A Shelat, et al.
Neurology|April 13, 2005
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severityR H S R Roxburgh, S R Seaman, T Masterman, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2021
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Claudia Rossig, Crystal Mackall, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohortSigbjørn Smeland, Stefan S Bielack, Jeremy Whelan, et al.
The Lancet. Oncology|August 30, 2016
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trialNeyssa M Marina, Sigbjørn Smeland, Stefan S Bielack, et al.
Pageof 57